Shares of Qualcomm Inc (NASDAQ: QCOM) closed out Monday’s session just above $167, extending a steady recovery that’s put it back near the upper end of its recent range. The stock is still up about 40% since April, even after a brief 9% pullback earlier this month, and remains one of the more resilient names in the semiconductor space. Much of that resilience has come amid a choppy backdrop for the sector, with capital flowing back and forth between AI winners like NVIDIA (NASDAQ: NVDA) and laggards trying to prove their relevance.
This resilience hasn’t come easy. While many of its bigger chipmaking peers have soared to new highs this year, Qualcomm continues to trade around the same levels it did in 2021. This is a reminder that, despite the progress seen in its diversification and AI-driven products, the market has yet to fully reward the company’s execution.
With earnings due in the first week of November, investors face a familiar dilemma: does Qualcomm finally have the momentum to break out, or is this rally running on borrowed time? Here’s how to think about the setup and two ways to think about trading it.
The Setup: Strong, But Unproven
Technically, Qualcomm is still holding its uptrend from the spring. Bulls have consistently stepped in to buy dips, and the ongoing rebound from the market-wide dip earlier this month has reinforced support around $155. The RSI did not reset from overbought territory in September, but it is also trending up from near-oversold levels earlier this month.
It currently has a healthily bullish reading of 55, suggesting that the bulls are in control and the stock has a lot of room to run.
It’s been stuck below a critical resistance zone near $180 for over a year. A decisive break above that level would mark Qualcomm’s first major breakout in a long time, but the company has struggled to sustain momentum each time it’s approached it.
Fundamentally, there’s plenty to like. Beyond smartphones, Qualcomm’s leadership team has made real progress diversifying into areas like connected vehicles, industrial IoT, and low-power edge computing.
These segments are growing faster than its legacy handset business and are key to reducing cyclicality in future earnings. It’s that diversification story that could ultimately reshape how investors value the stock.
Qualcomm’s valuation also remains compelling, with a price-to-earnings (P/E) ratio of about 16, a fraction of what peers like NVIDIA command. The company also boasts a consistent track record of beating Wall Street expectations, having topped both earnings and revenue estimates in every quarter for at least the past two years.
Still, sentiment remains fragile. Investors haven’t forgotten the stock’s long stretches of underperformance, even as it has made a solid shift in recent months.
Option 1: Buy Now and Bet on Another Beat
The bullish approach ahead of next month’s earnings is straightforward—lean into Qualcomm’s proven ability to beat expectations and start building a position now. The company has spent the past year expanding into automotive and IoT markets, with higher margins and less intense competition. Its recent acquisition of Arduino also strengthens its position in robotics and embedded hardware, which should add additional growth drivers.
If Qualcomm once again posts better-than-expected results and guides confidently on future growth, a push through $180 could come quickly. The broader market environment remains risk-on, with tech stocks leading into Q4, and that tailwind adds to the upside argument.
Option 2: Wait for Confirmation
The more cautious approach acknowledges that Qualcomm’s 40% rally since April might already have priced in a lot of optimism. Even with its attractive valuation, this stock has struggled to sustain breakouts and win over investors for the long term.
Waiting for confirmation, in the form of strong earnings and a clean move above $180, allows traders to avoid the volatility that often follows results. If Qualcomm disappoints, or even just meets expectations without offering bullish enough guidance, shares could easily retreat toward the $160 level.
Analysts have repeatedly praised Qualcomm’s execution, but there’s a growing sense that the company must prove it can translate innovation into sustained revenue growth. For those burned by its lack of follow-through, patience may be be the smarter choice.
The top small-cap signals for 2025 are already flashing — and once these moves begin, the entry window closes fast. Our free Wealth Building Report shows the signal pattern driving early momentum, the triggers to watch, and how to spot fast-moving setups before they accelerate.
Lululemon Athletica Inc (NASDAQ: LULU), once the darling of all retail stocks, has endured one of the ugliest downtrends in the industry this year. Its shares are down about 60% from their January peak, and every bullish rally attempt in the nine months since has been beaten back by the bears. Even though its revenue sits close to all-time highs, and its price-to-earnings (P/E) ratio is the lowest it’s ever been, the stock is still trading back at 2019 levels.
The good news for those on the sidelines is that the disconnect is becoming harder to justify. After months of relentless selling, there are signs the bears might finally be running out of steam. The key question is whether Lululemon has finally found a bottom—or if the stock is entering another extended downtrend. There are two compelling reasons to believe a bottom may be in place, and one reason that suggests caution is still warranted.
Technical Picture: Early Signs of a Bottom Forming
The first thing to note is that from a technical perspective at least, Lululemon is finally catching its breath and putting up a strong line of defense.. The stock hasn’t set a new low since the middle of September, and last week’s weakness was quickly bought up ahead of the weekend before it could retest those levels. Shares have already pushed higher to start the week, showing buyers are becoming more aggressive.
The stock’s Relative Strength Index (RSI) has also started climbing out of extremely oversold territory and trending upward in recent weeks, a classic sign that bearish momentum is fading. Combined with the fact that every dip since September has found higher short-term support, the evidence suggests the sellers may have exhausted themselves.
The long-term trend is still ugly, but the short-term behavior is actually quite bullish. As long as the $160 line continues to hold, there is, at the very least, a temporary bottom taking shape.
Analyst Support: Big Upside Targets Still in Play
The other reason adding weight to the argument that we’re looking at a solid entry opportunity is that even with sentiment crushed, not every analyst is throwing in the towel—far from it. Take Janine Stichter and her team from BTIG Research, for example, who reiterated their Buy rating last week along with a $303 price target.
In a note to clients, they flagged the room for operational improvement and execution gains, while wondering if the worst-case scenario is now baked into the stock. From Monday’s closing price around the $172 mark, they’re looking for a targeted upside of nearly 75% – not bad for a stock that’s been sinking like a stone for most of the year.
What makes that call even more compelling is the valuation reset already underway. Lululemon’s P/E ratio has plunged from nearly 30 at the start of 2025 to below 12 today, meaning it wouldn’t take much of an upside surprise in the next earnings report to spark a recovery. When you consider that Nike Inc (NYSE: NKE), another beaten-down retail stock, still trades at 35 times earnings, Lululemon’s risk/reward setup looks especially appealing right now.
Bear Case: Wall Street’s Skeptics Aren’t Done Yet
Still, it’s not all sunshine and rainbows. Several analysts remain unconvinced that Lululemon is out of the woods, and just last week, analysts from Bernstein cut their Outperform rating down to Market Perform.
They made the point that near-term catalysts are lacking and execution risk remains elevated.
The fact that they’re making that downgrade when the stock has already been down 60% since January carries weight.
But you can’t help but get the sense that the time to issue that warning was earlier in the year.
With the technical and price action now both suggesting a bottom forming in front of our eyes, we’re inclined to say actions speak louder than words.
Outlook: Cautious Optimism With a Clear Line in the Sand
For now, it’s a story of extremes: deeply oversold, widely doubted, but still fundamentally strong. Investors might have to pinch their noses for a while, but that is a potent combination for a comeback.
It could be tough to maintain the upward momentum if any more downgrades land in the coming weeks, but if shares can continue to hold above $160 into November, it would all but confirm that the bottom is already in.
Have you heard of this $1 ‘magic’ AI stock? They are building what some people are calling ‘ChatGPT with eyes’.
And it might be as revolutionary as the introduction of the iPhone was. But very few people have actually heard of this stock.
And there’s a weird, little-known way investors can get in for less than $1 / share. But hurry… the last chance to invest at their current valuation is October 30.
The stock market is giving off 2021 vibes. Many investors are swinging for the fences on stocks they can buy for $10 or less per share.
But if you have $1,000 to put into the market, there are several quality names that offer significant upside even though—in some cases—they’ve outperformed the market in 2025. In other words, if you’re looking for long-term growth, there are opportunities available that will allow you to generate a solid return without the volatility that can come with low-priced stocks.
Beyond their individual market niches, there’s a fundamental reason to choose these stocks. Analysts are projecting each of them to post earnings per share (EPS) growth of over 20% in the next 12 months. Earnings growth is the primary driver of stock price growth, so there’s still plenty of room for these three stocks to run.
Businesses are looking for alternatives to NVIDIA out of necessity, not as a critique of the way NVIDIA’s GPUs perform. However, they’re still looking for companies that are on the cutting edge of GPU design. Advanced Micro Devices checks that box and that’s reflected in the commitments made by OpenAI and Oracle.
AMD stock is up more than 92% in 2025. This may leave some investors to wonder if there’s still room to chase the stock, particularly since it’s trading slightly above the analyst consensus price target.
However, analysts are projecting over 36% earnings growth for AMD in the next 12 months, which makes the forward price-to-earnings (P/E) ratio of around 60x seem reasonable in the bloated tech sector.
Plus, the consensus price target is likely to move higher. In the 30 days ending Oct. 20, several analysts have increased their price targets. On Oct. 20, Bank of America raised its target from $250 to $300, and that 27% increase isn’t the largest increase. That goes to HSBC, which raised its target to $310 from $185, a whopping gain of over 42%.
Uber Stock: Profitable, Undervalued, and Expanding
Uber Technologies Inc. (NYSE: UBER) is an example of how patient investors have been rewarded. The company already commands over 70% of the ride sharing market, which remains its core business. And Uber Eats, once a pandemic necessity, is now a key revenue stream.
This has made the company solidly profitable, and it’s now generating solid free cash flow. Plus, as Uber continues to pay down its debt, it’s likely to begin rewarding shareholders with share buybacks and dividends.
UBER stock presents investors with an attractive setup. Analysts are projecting earnings growth of over 37% in the next 12 months. However, that growth exceeds the stock’s current forward P/E ratio of around 36x. That means that the stock may be undervalued at its current price, which is starting to be seen in analysts’ price targets.
LLY Stock: A Blue-Chip Buy-the-Dip Opportunity
Eli Lilly & Co. (NYSE: LLY) is the current leader in the GLP-1 market. Analysts forecast that the company may have over 50% of the obesity drug market by 2026. Eli Lilly continues to test for new indications such as sleep apnea and hear failure, which would expand the addressable market for these drugs.
But that’s not the only reason why investors should be bullish about LLY stock. The company had its Alzheimer’s disease drug, Donanemab, approved by the FDA in 2025. That’s already shown an ability to significantly slow cognitive decline in early Alzheimer’s patients. The company also has a deep pipeline that includes oncology and cardio metabolic drugs.
LLY stock is up just 4% this year as uncertainty surrounds the GLP-1 drug market. However, analysts forecast 32% growth in earnings over the next 12 months, which is in line with the company’s forward P/E ratio of around 34x. Plus, the stock already offers 19% upside from its current price, which is below the expectation of many analysts.
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund.
It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: “Brace yourselves. It’s about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you.”
This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.
The Night Owl is a financial newsletter that provides in-depth market analysis on stocks of interest to individual investors. Published by MarketBeat and Early Bird Publishing, The Night Owl is delivered around 9:00 PM Eastern Sunday through Thursday. If you give a hoot about the market, The Night Owl is the newsletter for you.